Wrestling with SUMO and bio-ontologies
To the editor: As researchers in bioinformatics turn increasingly to ontological tools and resources to help them to solve problems of information integration, data annotation, natural language processing and automated reasoning, the need for proven, useful ontologies in biomedical research will continue to grow exponentially. We are delighted to see Nature Biotechnology taking up this important issue, with the publication of a commentary on the MGED (Microarray Gene Expression Data Society) ontology in the September issue by Soldatova and King (Nat. Biotechnol. 23, [1095] [1096] [1097] [1098] 2005) .
Soldatova and King make the important point that ontology builders need to be aware of emerging standards and best practices. When they trace the origins of modern work on ontology to Aristotle, however, it is important to remember that philosophers have been debating Aristotle's categories continuously for more than two millennia. The number of ways in which we can slice up the world into categories is in practice unlimited, and it is not always obvious which distinctions one needs to make, for the purposes of the MGED ontology, or for any other purpose. Moreover, finding problems in virtually any extant ontology is a trivial exercise. Soldatova and King recommend the use of the Suggested Upper Merged Ontology (SUMO) as an emerging standard with the capacity to bring coherence to ontologies in the biomedical domain. Unfortunately, SUMO in its current form embodies no welldefined criteria to determine which classes should be properly included within its scope, with unfortunate consequences for its overall integrity and usability for purposes of ontology integration in the life sciences. Should an upper ontology designed for purposes of robust integration of biomedical ontologies include classes such as Monkey or BodyCovering? Or odd disjunctive classes, such as FruitOrVegetable?
It is self-evident that methods to assist the empirical evaluation of both ontology content and structure are urgently required. As Soldatova and King themselves acknowledge, "the engineering of ontologies is still a relatively new research field."
Much of the most influential ontology work in biomedicine has been stimulated by the pressing needs of bench biologists themselves in managing burgeoning quantities of data.
As a consequence, many of the ontologies developed thus far are somewhat unprincipled in comparison to what we now know can be achieved. Today, however, we have reached the point where an increasing number of biomedical scientists are recognizing the importance of learning about standards of good practice in ontology development and of adhering to those standards whenever possible. 1 The newly created National Center for Biomedical Ontology 2 , formed under the US National Institutes of Health (NIH) roadmap, is a direct acknowledgment of this need. We are principal participants of this center and have a particular interest in improving the quality of all ontologies developed for use in biomedicine. The center will be attempting, through systematic outreach activity and through testing and dissemination of good ontology practices, to aid biomedical investigators in the construction of ontologies that adhere to proven conventions and knowledge-representation formalisms 3 . We will conduct workshops designed to promote collaboration among different groups of ontology developers and to assist biomedical researchers in developing and applying ontologies precisely tailored to their needs. We believe that the establishment of the center will offer an opportunity to enhance consistency and clarity in biomedical ontologies and to increase the prospects for their interoperability, for example, through the use of common, well-defined relationships along the lines applied to all new entries in the Open Biomedical Ontologies library 4, 5 .
The central role of good ontologies in biomedical informatics is unquestioned. What we need now is research to establish how best to achieve our broader goals through the formalization and integration of biomedical knowledge. 
To the editor:
As researchers involved in the development of the MGED Ontology (MO) and other bio-ontologies, we were pleased to see Nature Biotechnology foster dialogue on the challenges in building robust and optimal ontologies for biomedical research in a commentary by Soldatova and King published in the September issue (Nat. Biotechnol. 23, [1095] [1096] [1097] [1098] 2005) . However, we wish to address several misleading and inaccurate descriptions of the development and use of the MO, and comment on the motivation behind and constraints inherent in the development of such bio-ontologies.
Ontology development in biology has a good track record for addressing real and immediate needs for describing and classifying biological and experimental data-genes, proteins, experiments, tissues, treatments, functions. It has done this in a
C O R R E S P O N D E N C E
manner that affords straightforward, reliable and increasingly automated access to both data and the methods by which they were generated, and is helping to meet the timecritical demands of current research. The MO is one of the early examples of an ontology that was developed by a community in that spirit, specifically to describe microarray experiments. In their commentary, Soldatova and King show no awareness of the challenges posed by rapidly evolving, high-throughput genomic technologies that are generating data at an exponentially increasing rate. Controlled terminology as provided through an ontology was urgently required for the description of microarray experiments; biologists did not expect emerging ontologies to be ideally engineered, and we would be the first to state that the MO contains compromises. In the absence of such controlled terminology, much of the data being generated today would not be available in a form readily amenable to comparative analysis, either now or in the future.
Fundamental inaccuracies in this critique appear to reflect a lack of understanding of the MO's nature. For example, the authors state that the MO "has been promoted as an international standard." The MAGE object model is an international standard for exchange of microarray data. The MO was developed to provide terminology required to support the annotation of microarray experiments in areas where the MAGE Object Model does not provide descriptors. Furthermore, the authors state that the Minimum Information About a Microarray Experiment (or MIAME) specification is at the root of some of the design compromises in the MO. This is a puzzling assertion; surely they meant to refer to the MAGE Object Model, from which some of the classes in the MO were created.
The authors suggest rebuilding the MO. But the benefits of such refactoring need to be weighed against the necessity of maintaining a stable real-world resource that is widely applied in software implementations. This is in fact the reason why there is a 'core' component to the MO deliberately held stable-a design decision that seems to be misunderstood by the authors. Additionally, the Functional Genomics Ontology (or FuGO; http:// fugo.sf.net) project is now underway to collaboratively develop controlled terminology for transcriptomics, proteomics and metabolomics, as used in a range of biologically defined domains. The decomposition and reuse of the MO will be part of the process of building FuGO, allowing the MO itself to remain stable, continuing to serve its established user base.
The authors suggest the building of ontologies that are (i) purpose independent and (ii) compliant with a standard upper ontology. These 'key rules for bio-ontology development' represent unrealistic expectations of the current state of play as the adoption of an upper ontology is predicated on its acceptance by user communities who must decide whether or not an upper ontology is fit for its intended purpose. There are many 'standard' upper level ontologies. Such ontologies are themselves subject to major philosophical debate. In addition, a valid demonstration of their utility in ontology building is by no means universally accepted, even within the computer science community.
Finally, we address perhaps our greatest concern with respect to this commentary: the article centers on the "isolation of bio-ontologies from the larger world of ontologies" and asserts the need for interaction between MO developers and other ontologists. It is therefore ironic, and of notable concern, that the authors of this commentary have never communicated their analysis, or suggestions for improvements to any of the extended family of MO developers, that includes ontologists in an advisory capacity. This sort of collaborative resource development is not a competitive exercise. We have ongoing interactions with a number of leading ontologists, and we encourage other researchers to contact us (http://mged. sourceforge.net/ontologies/) to share their views and help ensure that good ontologies, which benefit the bioscience community, are developed as effectively and efficiently as possible.
